Wireless Revolution Attracts New Health Care Partners

While device manufacturers look for ways to utilize wireless technology to enhance the use of their products, a number of nontraditional health care partners are emerging as important players in the market. Firms such as Qualcomm, AT&T, and other telecommunication companies are working to establish an infrastructure that will make it easier and safer for patient data to flow from remote devices to caregivers. These technology firms have already established deals and partnerships with some manufacturers, and although there is still a lot of work that needs to be done, their presence in this market is an important step that could hasten the ongoing wireless health care revolution.

As health care’s quest to embrace the wireless revolution continues, the demands on medical devices are changing, and the industry is seeing a significant increase in the number of companies and products – at various stages of development – that utilize mobile technology. A good deal of emphasis is being placed on patient-monitoring devices designed to be used outside health facility walls. Although the types of information these devices measure are not really changing, the way the data is transmitted and utilized is poised to change how care is delivered. The players involved in this technology-based transformation are also shifting, as many of the large communication companies are not only becoming heavily invested in the process, but also are taking lead roles in the market’s direction.

One of the biggest names active in this evolving field is Qualcomm Inc., which established a new business unit, Qualcomm Life Inc., in late 2011 for the sole purpose of...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from United States

DeepLook AI Imaging Provides A Deeper Look At Dense Breast

DeepLook Medical recently announced the commercial rollout of DL Precise, an AI-powered imaging platform that enhances breast cancer screening, at major healthcare institutions across the US.

First AI Breast Cancer Prediction Platform Receives FDA Authorization

 

Clairity’s "first-in-class" mammography-based AI screening tool, Clairity Breast, provides "equitable risk assessments," expanding access to lifesaving early detection for breast cancer, said company founder Connie Lehman.

SAGA Diagnostics Launches Early Breast Cancer MRD Detection Test In US

 

SAGA Diagnostics has launched its breast cancer residual and recurrence detection test – Pathlight – in the US. The test’s ultrahigh sensitivity and specificity is rare to see in oncology, the company claimed.

ConcertAI Launches Generative AI-Powered Precision Suite

 

Valued at over $1.9bn, ConcertAI is building on its pre-existing multi-agentic AI SaaS solution CARAai to bring life science customers the new Precision suite of applications: Precision Explorer, Precision Trials, Precision GTM and Precision360.

More from North America

Get Ready For International Harmonization Before Approaching QMSR Deadline, Says Regulatory Expert

 

During MD&M East last week, regulatory consultant Darren Reeves reminded device manufacturers that the time to get ready to comply with the new Quality Management System Regulation is now.

Zika Virus Test Among 4 New FDA Device Classifications

 
• By 

The FDA plans to announce class II status for four new device types, including tests for the Zika virus and genetic condition Fragile X. This follows earlier announcements and highlights a trend toward diagnostic classifications. The classifications are considered deregulatory, meaning they will hel

FDA Draft Guidance Introduces Electric Submission For Q-Sub Process

 

The US FDA says its updated draft guidance represents one of several steps the agency is taking to develop electronic submission templates for the medical device industry. The document introduces stakeholders to currently available resources for supporting their pre-subs to the agency.